A33scFV-cytosine deaminase: A recombinant protein construct for antibody-directed enzyme-prodrug therapy

P. M. Deckert, C. Renner, L. S. Cohen, A. Jungbluth, G. Ritter, Joseph Bertino, L. J. Old, S. Welt

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.

Original languageEnglish (US)
Pages (from-to)937-939
Number of pages3
JournalBritish Journal of Cancer
Volume88
Issue number6
DOIs
StatePublished - Mar 24 2003

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • A33 antibody
  • Antibody
  • Colon carcinoma
  • Directed enzyme-producing therapy (ADEPT)
  • Recombinant fusion proteins
  • Tumour targeting

Fingerprint Dive into the research topics of 'A33scFV-cytosine deaminase: A recombinant protein construct for antibody-directed enzyme-prodrug therapy'. Together they form a unique fingerprint.

Cite this